Xiang Guang-da

Quick facts

Marketed products

• metformin 0.85 twice daily for 6 months · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.

Phase 2 pipeline

• continuous intra-femoral thrombolysis group
• conventional multifactorial therapy group
• Intensive multifactorial group

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Xiang Guang-da portfolio CI brief
• Xiang Guang-da pipeline updates RSS